Equity Overview
Price & Market Data
Price: $23.12
Daily Change: -$1.02 / 4.41%
Daily Range: $22.84 - $24.34
Market Cap: $216,424,016
Daily Volume: 11,659
Performance Metrics
1 Week: -10.94%
1 Month: 4.47%
3 Months: -11.08%
6 Months: 56.96%
1 Year: 85.61%
YTD: 25.93%
Company Details
Employees: 10
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Sugar Land, Texas.